Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Acalabrutinib, Lenalidomide, and Rituximab (aR2) in Patients With Previously Untreated Follicular Lymphoma

NCT04404088 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04404088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04404088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Acalabrutinib, Lenalidomide, and Rituximab (aR2) in Patients With Previously Untreated Follicular Lymphoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
July 16, 2020
Completion date
March 1, 2028
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage iii grade 1 follicular lymphoma, ann arbor stage iii grade 2 follicular lymphoma, ann arbor stage iii grade 3 follicular lymphoma, ann arbor stage iv grade 1 follicular lymphoma, ann arbor stage iv grade 2 follicular lymphoma, ann arbor stage iv grade 3 follicular lymphoma, grade 3a follicular lymphoma